EASD 2026: Petrelintide pairs 10.7% weight loss with placebo-like GI tolerability

Results from the Phase II ZUPREME-1 trial (NCT06662539) assessing petrelintide were presented at EASD 2026 in Milan, Italy. ZUPREME-1 positions petrelintide as a tolerability-led rather than efficacy-led entrant. The trial evaluated the efficacy, safety, and tolerability of multiple doses of petrelintide for long-term use in obese patients. Credit: Halfpoint via Shutterstock.com. Unlock FREE Access to Premium Content ​Discover exclusive forecasts, analyst insights, and in-depth clinical trials industry analysis across drug development, clinical research, and trial innovation. With a free Clinical Trials Arena profile, you can: Experience unmatched clarity with a single platform that combines unique data, AI, and human expertise.…

Source: Clinical Trials Arena